Papers on
apolipoprotein A-I
High-density lipoprotein function, dysfunction, and reverse cholesterol transport.Smith et al., New York City, United States. In Arterioscler Thromb Vasc Biol, Dec 2012
Raising HDL levels in animal models by infusion or overexpression of apolipoprotein A-I has shown clear vascular improvements, such as delayed atherosclerotic lesion progression and accelerated lesion regression, along with increased reverse cholesterol transport.
Approach to the patient with extremely low HDL-cholesterol.deGoma et al., Philadelphia, United States. In J Clin Endocrinol Metab, Oct 2012
Confirmation of HDL-C levels below 20 mg/dl in the absence of severe hypertriglyceridemia should be followed by evaluation for secondary causes, such as androgen use, malignancy, and primary monogenic disorders, namely, apolipoprotein A-I mutations, Tangier disease, and lecithin-cholesterol acyltransferase deficiency.
Lipid-related markers and cardiovascular disease prediction.Danesh et al., In Jama, Jul 2012
OBJECTIVE: To determine whether adding information on apolipoprotein B and apolipoprotein A-I, lipoprotein(a), or lipoprotein-associated phospholipase A2 to total cholesterol and high-density lipoprotein cholesterol (HDL-C) improves cardiovascular disease (CVD) risk prediction.